Eli Lilly (LLY)
(Delayed Data from NYSE)
$921.49 USD
+6.45 (0.70%)
Updated Sep 20, 2024 04:02 PM ET
After-Market: $920.77 -0.72 (-0.08%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
LLY 921.49 +6.45(0.70%)
Will LLY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LLY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LLY
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?
LLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU
Roche Antiviral Drug Reduces Transmission in Late-stage Study
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
Other News for LLY
Janus Henderson Concentrated Growth Managed Account Q2 2024 Commentary
Janus Henderson Concentrated All Cap Growth Managed Account Q2 2024 Commentary
Eli Lilly Is Finally Cheap, Warranting An Upgrade To Buy
Eli Lilly: A Strong Buy Amidst Obesity Treatment Market Dominance and Expanding Pipeline
Eli Lilly & Co: Maintaining Market Dominance with Orforglipron Amid Competitor Challenges